Table I.
Preclinical studies of anti-glioma chemotherapeutics.
| Author (year) | Agent | In vivo/In vitro | Combination therapy | Treatment effect | (Refs.) |
|---|---|---|---|---|---|
| Wang et al, 2016 | TMZ | In vitro | - | Inhibiting proliferation, migration and invasion | (35) |
| Da Ros et al, 2018 | TMZ | In vitro | Aldoxorubicin | Enhancing the killing effect of TMZ on TMZ-resistant glioma cells | (36) |
| Shi et al, 2020 | TMZ | Both | Polymer micelle | Inhibiting cell viability and prolonging the survival time of U87 mice | (16) |
| Hu et al, 2021 | TMZ | - | NF-κB and MGMT inhibitors | Downregulating MGMT and improving TMZ sensitivity | (37) |
| Wu et al, 2021 | TMZ | In vitro | Talazoparib | Inhibiting the proliferation and downregulating MGMT and poly (ADP-ribose) polymerase | (38) |
| Rahman et al, 2019 | TMZ | Both | Bortezomib | Inhibiting the proliferation, MGMT, MGMT mRNA and nuclear phosphorylation/activation p65. Prolonging the survival time of mice | (39) |
| Rezaei et al, 2020 | BCNU | In vitro | miR-181a | Inhibiting cell proliferation and migration. Promoting apoptosis | (40) |
| Lu et al, 2016 | Nimustine | In vitro | Hyperbaric oxygen | Inhibiting tumor growth and reducing the tumor volume | (41) |
| Yi et al, 2019 | BCNU | Both | Metal nanoparticles | Inhibiting proliferation and decreasing the survival rate. Targeting efficiency is higher | (42) |
| Ashrafzadeh et al, 2020 | Cisplatin | Both | OX26 monoclonal antibody and liposomes | Increasing the uptake of C6 cells. Improving the mean survival time and reducing toxicity | (43) |
| Zhang et al, 2017 | Cisplatin | In vitro | Nanoparticles and convection-enhanced delivery | The distribution volume of the brain was higher and prolonging the survival time of rats | (44) |
| Thakur et al, 2020 | Doxorubicin | In vitro | Exosomes | Inhibiting the proliferation | (45) |
| Meng et al, 2019 | Doxorubicin | Both | Nano-micelle | Inhibiting the proliferation and inducing apoptosis. Reducing the tumor volume and increasing drug accumulation | (46) |
| Zhang et al, 2017 | Doxorubicin | In vivo | Liposomes and vincristine | Reducing the tumor volume and prolonging the median survival time | (27) |
| Park et al, 2016 | Vincristine | In vitro | - | Inhibiting glioma cell proliferation and glioma angiogenesis | (47) |
| Fu et al, 2019 | Vincristine | Both | Nanoparticles | Increasing the toxic effect of vincristine. Reducing tumor and prolonging the mean survival time | (48) |
| Wu et al, 2016 | Vincristine | Both | Solid nano-lipid particles, NLCS and TMZ | The inhibition effect of NLCS was the strongest and inhibiting tumor growth | (49) |
| Koosha et al, 2017 | Topotecan | In vitro | A966492 and radiation | Decreasing the cell survival rate and increasing the radiation lethal effect | (50) |
| Sharon and Rubinstein, 2021 | Topotecan | In vitro | CaCl2 and PLGA microspheres | Decreasing the relative survival rate of cells and increasing the toxic effect of topotecan | (51) |
TMZ, temozolomide; MGMT, O6-methylguanine-DNA methyltransferase; NLCS, nano-lipid carriers; BCNU, carmustine.